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In mammals, long-range gene regulation became apparent through simple Mendelian disease genetics in
human and developmental genetics in the mouse. Can the insights into gene control, provided by the study
of these enhancers, help us understand the functional significance of sequence variation associated with
common/complex human disease and quantitative traits?Enhancers are cis-regulatory DNA se-
quences capable of inducing transcrip-
tion from a distant promoter and can be
located either upstream or downstream
of the activated gene. A plethora of such
candidate cis-regulatory regions are
being identified through their chromatin
signatures, including DNase hypersensi-
tivity, histone variants (H2A.Z), histone
modifications (histone H3 lysine 4 mono-
or dimethylation, histone H3 lysine 27
acetylation), bound cofactors (p300,
mediator), and even RNA polymerase II
itself. Functional studies are still in their
infancy, but tissue-specific enhancer
activity for a number of noncoding se-
quences has been demonstrated using
transgenic assays. Sequence conserva-
tion across species is also a guide to the
genomic location of some, but not all,
enhancers (Blow et al., 2010).
The Role of Distal Enhancers
in Evolution and Development
How did such cis-regulatory sequences
evolve? Whereas simple elements that
bind few factors may have arisen de
novo by small base changes, it seems
unlikely that complex enhancers could
have arisen this way. Possible routes are
the exaptation of retroposons to form
clusters of protein-binding motifs at new
genomic locations (Santangelo et al.,
2007; Sasaki et al., 2008) or the acquisi-
tion of novel regulatory functions by
promoters of archaic geneswhose coding
sequences have been subsequently lost.
Existing enhancers may also evolve to
acquire new functions in development.
What are the evolutionary conse-
quences of mutation and/or deletion of
existing enhancers? Whereas alteration
of coding regions may have quite blunteffects on protein function, alterations at
enhancers have the potential to subtly
adjust levels of gene expression—a situa-
tion required for the evolution of quantita-
tive traits and response to environmental
stresses. Moreover, phenotypic effects
of mutating enhancers can be confined
to discrete tissues or developmental
stages and so could allow a preexisting
gene to be harnessed to a new develop-
mental scenario (Rebeiz et al., 2009). For
instance, neural-specific activation of
Lunapark and Evx2, situated between
the HoxD cluster and the global control
region (GCR), is regulated by enhancer
elements within the GCR. Co-option of
the GCR to then facilitate HoxD13-10 ex-
pression during limb development may
have been due to the accrual of mutations
to produce an element able to function in
the developing limb (Gonzalez et al.,
2007). A limb-specific enhancer of Prx1—
which promotes bone elongation in the
forelimb—is responsible for higher tran-
scription levels and more extensive
expression domains at key limb bud loca-
tions and embryonic stages in the fruit bat
(Cretekos et al., 2008). Replacing the
endogenous mouse enhancer with the
bat equivalent produced mouse embryos
with longer forelimbs but no morpholog-
ical effects in other organs where Prx1 is
expressed. Similarly, in transgenic mouse
assays, human-specific point mutations
within a highly conserved noncoding
element (HACNS1) confer a limb expres-
sion pattern, including the presumptive
anterior wrist and proximal thumb, that
appears human-specific compared to
that conferred by orthologous sequences
from nonhuman primates (Noonan and
McCallion, 2010). Human-specific dele-
tions, of mostly noncoding sequencesDevelopmental Cthat are highly conserved between chim-
panzees and other mammals, include
regions near the androgen receptor
locus and the neural-specific GADD45G
(McLean et al., 2011). These contain
tissue-specific enhancers whose loss
correlates with human-specific traits:
loss of secondary sexual characteristics
associated with androgen signaling and
the expansion of specific brain regions.
The Genomic Context of Enhancers
A sizeable proportion of enhancers are
situated tens to hundreds (even thou-
sands) of kilobases from their target
genes, often in large gene-poor regions.
Indeed, many genes with tight spatial
and/or temporal expression domains
tend to be located adjacent to such
gene deserts. The absence of other
neighboring genes could help ensure
regulatory specificity between enhancer
and promoter. An example of problems
that can arise from the promiscuous
action of enhancers placed within gene-
rich domains is illustrated by the ectopic
activation of neighboring genes when
the b-globin locus control region (LCR)
is integrated into a gene-rich domain
of housekeeping genes (Noordermeer
et al., 2008).
However, there must be specificity
between some enhancers and promoters.
The sonic hedgehog gene (Shh), which
codes for a morphogen directing cell
fate in several tissues during organogen-
esis, is adjacent to a gene desert contain-
ing at least three enhancers that are active
only within Shh-expressing tissues of the
embryonic brain. However, Shh expres-
sion during limb development is regulated
by another enhancer, the zone of polar-
izing activity regulatory sequence (ZRS),ell 21, July 19, 2011 ª2011 Elsevier Inc. 17
Figure 1. The Sonic Hedgehog Regulatory Region and Possible Mechanisms of Enhancer Activity
(A) Linear representation of genes (green boxes) at the Shh locus showing the location of long-range neural-specific and limb-specific enhancers (black boxes).
(B) Models of enhancer-promoter communication. Factors bound to the enhancer and promoter recruit chromatin-modifying factors that: reorganize the
intervening chromatin, with the factors themselves being the signal for gene activation (left), enable direct enhancer-promoter interaction by the formation of
chromatin ‘‘mini-loops’’ (middle), or allow for spatial colocalization of the enhancer and promoter, with looping out of the intervening chromosomal region (right).
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the neural enhancers and within an intron
of another gene (Lettice et al., 2003)
(Figure 1A). The ZRS bypasses both
the gene in which it is located and
a neighboring gene in order to activate
only Shh.
How Do Long-Range Enhancers
Activate Target Genes?
Enhancers are clusters of transcription
factor (TF) binding sites. There have been
three, not entirely mutually exclusive,
mechanisms proposed for enhancer-
gene communication (Figure 1B). In the
first, sequence-specific factors bound to
the enhancer and/or promoter recruit
further factors—perhaps even including
RNA polymerase—to reorganize chro-
matin throughout the intervening region
as the signal for gene activation (Bulger
and Groudine, 2010). Due to the large
genomic distances involved, and even18 Developmental Cell 21, July 19, 2011 ª20intervening promoters, this is unlikely to
be a feasible mechanism for very long-
range control, such as that at Shh. The
secondmechanismalso involves reorgan-
izing the intervening chromatin, but to
allow for direct enhancer-promoter inter-
action, possibly through a series of
‘‘mini’’ chromatin loops.
The third mechanism invokes the
spatial colocalization in the nucleus of
the enhancer and promoter, which can
then directly interact with each other if
the necessary factors are bound, looping
out the intervening region. An attractive
feature of this model is that it ensures
that an enhancer can activate the expres-
sion of only one gene at a time. However,
enhancer-promoter mediated looping
may be insufficient for gene activation.
Nuclear colocalization of the ZRS and
Shh is observed in both expressing and
nonexpressing halves of the developing
limb bud, but on the posterior side, the11 Elsevier Inc.active Shh locus is additionally extruded
from its chromosome territory (Amano
et al., 2009). A similar looping out from
chromosome territories is induced by an
ectopic b-globin LCR (Noordermeer
et al., 2008).
Does there need to be direct physical
interaction between enhancer and
promoter for activation of gene expres-
sion? Clustered TF binding sites at
enhancers might simply act to reduce
the effective nuclear search space of
these proteins for a promoter by diffu-
sion/nonspecific binding. Enhancer-
promoter specificity would then rely
upon shared high-affinity binding sites
for the same set of factors. Moreover,
enhancers themselves often bind RNA
polymerase II (De Santa et al., 2010) and
produce short noncoding (nc) RNAs (Kim
et al., 2010). Whether all such ncRNAs
have a function in vivo is still to be
determined.
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Mutations associated with b-thalas-
saemia, an inherited disorder caused by
altered expression of globin genes, were
what first led to the identification of the
b-globin LCR. Deletions that affect an
enhancer’s function, or translocations
that separate enhancers from their
cognate promoters, are also the cause
of several simple Mendelian human
genetic diseases (Noonan & McCallion,
2010). Point mutations in the Shh ZRS in
preaxial polydactyly result in a gain of
function of enhancer activity and ectopic
activation of Shh expression in the ante-
rior limb bud (Lettice et al., 2003).
However, almost half of single nucleo-
tide polymorphisms (SNPs) that show
statistical associations with common/
complex human disease and quantitative
traits in genome-wide association studies
(GWAS) are within noncoding regions
and gene deserts and thus potentially
involve enhancers (Noonan and McCal-
lion, 2010). For example, a SNP within an
intronic enhancer ofRET confers a greater
risk of Hirschsprung disease than the
major allele. SNPs in a gene desert
330 kb upstream of the c-myc protoonco-
gene are associated with greater risk
of several cancers (Wasserman et al.,
2010). Why might so much of the genetic
variation apparently associated with
complex human disease be in enhancers?
Whereas point mutations in protein cod-
ing regions can completely ablate gene
function and so produce strong and pene-
trant phenotypes, point mutations in an
enhancer may alter binding affinity for
a specific TF and so result in only subtle
changes in the level, time, or place of
gene expression. The resulting phenotype
could therefore be more modest and
subject to interaction with other genes
and with the environment.
Future Prospects
Our current lack of mechanistic under-
standing about how enhancers regulatetemporal and spatial patterns of expres-
sion from the correct target gene is
impeding exploitation of the investments
made in GWAS and the functional
analysis of human disease. What needs
to be done to better understand how
enhancerswork? The dearth of knowledge
on enhancer biochemistry needs to be
addressed in order to gain a more com-
plete understanding of how enhancers
integrate and process signaling informa-
tion that promotes transcription. Enhancer
elements function as nucleoprotein
complexes, with multiple associated se-
quence-specific and nonspecific binding
proteins. What are these proteins and
how do they act together? There could be
a high level of cooperative and coordinate
action between the bound TFs to give
unitary outputs to the transcriptional ma-
chinery, or they may instead form multiple
functional units that each independently
regulate gene expression. In the former
case, mutation of individual factor binding
sitesmayablateenhancer function,where-
as in the latter case they would be less
detrimental to enhancer function.
The precise chronological sequence of
chromatin events at enhancers is also to
be elucidated. Do direct physical
enhancer-promoter interactions only
occur once factors are bound to both
elements, or does the interaction itself
contribute to the loading of TFs or tran-
scriptional machinery to the promoter?
Current assays for long-range physical
interactions—fluorescence in situ hybrid-
ization (FISH) and chromosome confor-
mation capture (3C) and its derivatives—
only give snapshots or cell population-
averaged information, respectively. There
is a need for dynamic assays of chromo-
some organization to capture long-range
interactions as they occur in real time.
There is also a need for these techniques
to be coupled to methods for quantifying
levels of gene expression in single cells
at defined times and places in differentia-
tion and development.Developmental CREFERENCES
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